Genelabs, Syntello Inc. deal

Mark Van Asten, director of business development in GNLB's diagnostic division, said GNLB received an exclusive license because of its proprietary position in the more prevalent HTLV 1 virus. Genelabs Diagnostics currently markets several recombinant protein-based diagnostic products used in the screening and confirmation of HTLV infection. HTLV I is endemic in many parts of Asia and the less prevalent HTLV II has a high incidence in IV drug users. ...